Stoke Therapeutics Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Stoke Therapeutics Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cash flows from operating activities: | ||||||||||||||||||||||||
| net income | -23,482,000 | 112,879,000 | -10,482,000 | -26,430,000 | -25,695,000 | -26,374,000 | -26,958,000 | -24,542,000 | -30,654,000 | -22,545,000 | -25,655,000 | -26,111,000 | -24,652,000 | -24,649,000 | -24,448,000 | -22,597,000 | -21,967,000 | -16,793,000 | -14,561,000 | -13,684,000 | -12,959,000 | -11,039,000 | -10,160,000 | -8,604,000 |
| adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||||||
| depreciation | 446,000 | 477,000 | 526,000 | 540,000 | 548,000 | 563,000 | 624,000 | 637,000 | 611,000 | 597,000 | 609,000 | 388,000 | 302,000 | 247,000 | 235,000 | 254,000 | 249,000 | 236,000 | 237,000 | 234,000 | 224,000 | 193,000 | 139,000 | 126,000 |
| amortization and accretion of marketable securities | 527,000 | -494,000 | -782,000 | -547,000 | -289,000 | -24,000 | -89,000 | -122,000 | -146,000 | 32,000 | -151,000 | -102,000 | -193,000 | 235,000 | 57,000 | 49,000 | ||||||||
| stock-based compensation | 7,598,000 | 6,753,000 | 7,139,000 | 7,494,000 | 7,427,000 | 5,410,000 | 6,058,000 | 6,552,000 | 6,760,000 | 5,887,000 | 5,790,000 | 5,926,000 | 6,163,000 | 4,975,000 | 4,686,000 | 4,614,000 | 4,452,000 | 2,698,000 | 1,580,000 | 1,785,000 | 1,649,000 | 754,000 | 712,000 | 731,000 |
| reduction in the carrying amount of right of use assets | 612,000 | 599,000 | 582,000 | 571,000 | 562,000 | 550,000 | 591,000 | 563,000 | 556,000 | 550,000 | 543,000 | 536,000 | 533,000 | 377,000 | 386,000 | 322,000 | 277,000 | 271,000 | 266,000 | 262,000 | 257,000 | 253,000 | ||
| changes in assets and liabilities: | ||||||||||||||||||||||||
| prepaid expenses and other current assets | -3,850,000 | -2,555,000 | -1,443,000 | 600,000 | -644,000 | -349,000 | 1,353,000 | -514,000 | 1,778,000 | -2,088,000 | -1,528,000 | 581,000 | -971,000 | -3,265,000 | -778,000 | 228,000 | -1,223,000 | -1,078,000 | -2,823,000 | -80,000 | 949,000 | -924,000 | 863,000 | -1,866,000 |
| accounts payable, accrued liabilities and lease liabilities | 2,765,000 | 4,741,000 | -749,000 | 3,577,000 | -1,919,000 | |||||||||||||||||||
| deferred revenue | -10,038,000 | 9,427,000 | -20,912,000 | -3,094,000 | -2,963,000 | -2,423,000 | -1,079,000 | -1,854,000 | 3,722,000 | -4,140,000 | -2,180,000 | -1,928,000 | -2,170,000 | 58,014,000 | ||||||||||
| net cash from operating activities | -25,422,000 | 131,827,000 | -23,193,000 | -21,615,000 | -17,477,000 | -24,566,000 | -20,649,000 | -17,262,000 | -21,800,000 | -21,356,000 | -22,373,000 | -22,056,000 | -19,928,000 | 32,491,000 | -16,258,000 | -14,682,000 | -15,831,000 | -20,136,000 | -10,931,000 | -10,873,000 | -9,646,000 | -10,771,000 | -10,201,000 | -8,048,000 |
| capex | -154,000 | -152,000 | -42,000 | -103,000 | -46,000 | -12,000 | -229,000 | -383,000 | -839,000 | -165,000 | -409,000 | -2,030,000 | -682,000 | -841,000 | -203,000 | -273,000 | -520,000 | -204,000 | -90,000 | -269,000 | -81,000 | -610,000 | -568,000 | -583,000 |
| free cash flows | -25,576,000 | 131,675,000 | -23,235,000 | -21,718,000 | -17,523,000 | -24,578,000 | -20,878,000 | -17,645,000 | -22,639,000 | -21,521,000 | -22,782,000 | -24,086,000 | -20,610,000 | 31,650,000 | -16,461,000 | -14,955,000 | -16,351,000 | -20,340,000 | -11,021,000 | -11,142,000 | -9,727,000 | -11,381,000 | -10,769,000 | -8,631,000 |
| cash flows from investing activities: | ||||||||||||||||||||||||
| purchases of marketable securities | -181,553,000 | -19,016,000 | -29,139,000 | -49,901,000 | 4,870,000 | -9,706,000 | -52,543,000 | -143,941,000 | 0 | -4,991,000 | ||||||||||||||
| purchases of property and equipment | -154,000 | -152,000 | -42,000 | -103,000 | -46,000 | -12,000 | -229,000 | -383,000 | -839,000 | -165,000 | -409,000 | -2,030,000 | -682,000 | -841,000 | -203,000 | -273,000 | -520,000 | -204,000 | -90,000 | -269,000 | -81,000 | -610,000 | -568,000 | -583,000 |
| sales of marketable securities | 33,230,000 | 32,800,000 | 30,000,000 | 20,000,000 | 0 | 10,000,000 | 15,000,000 | 15,000,000 | 24,312,000 | 53,250,000 | 18,029,000 | 79,000,000 | 53,371,000 | 9,000,000 | ||||||||||
| net cash from investing activities | -148,477,000 | 13,632,000 | 819,000 | -30,004,000 | -88,278,000 | 9,988,000 | 14,771,000 | 14,617,000 | 23,473,000 | 53,085,000 | 22,490,000 | 67,264,000 | 146,000 | -135,782,000 | 11,797,000 | -5,264,000 | -82,755,000 | -204,000 | -90,000 | -269,000 | -81,000 | -610,000 | -569,000 | -583,000 |
| cash flows from financing activities: | ||||||||||||||||||||||||
| proceeds from employee stock purchase plan | 0 | 370,000 | 0 | 364,000 | 0 | 168,000 | 1,000 | 348,000 | 53,000 | 153,000 | 0 | 401,000 | 0 | 169,000 | 0 | 334,000 | 0 | 175,000 | 0 | |||||
| proceeds from issuance of common stock upon exercise of stock options | 554,000 | 1,004,000 | 567,000 | 139,000 | 766,000 | 250,000 | 4,000 | 214,000 | -5,000 | 158,000 | 42,000 | 33,000 | 326,000 | 93,000 | 172,000 | 73,000 | 161,000 | 371,000 | 1,595,000 | 681,000 | 368,000 | 199,000 | 19,000 | |
| proceeds from issuance of common stock in controlled equity offering sales agreements | 7,656,000 | |||||||||||||||||||||||
| proceeds from follow-on offering, net of underwriting discounts, commissions and offering costs | 0 | 0 | ||||||||||||||||||||||
| net cash from financing activities | 554,000 | 1,374,000 | 568,000 | 8,159,000 | 120,650,000 | 1,717,000 | 7,343,000 | 562,000 | 48,000 | 45,054,000 | 43,000 | 434,000 | 3,425,000 | 42,507,000 | 171,000 | 408,000 | 159,000 | 546,000 | 106,868,000 | 673,000 | 369,000 | 198,000 | 192,000 | -1,000,000 |
| net increase in cash, cash equivalents and restricted cash | -173,345,000 | 146,833,000 | -21,806,000 | -43,460,000 | 14,895,000 | -12,861,000 | 1,465,000 | -2,083,000 | 1,721,000 | 76,783,000 | -19,794,000 | 95,847,000 | -10,469,000 | -10,578,000 | -9,631,000 | |||||||||
| cash, cash equivalents and restricted cash—beginning of period | 0 | 128,780,000 | 0 | 0 | 192,011,000 | 0 | 0 | 114,125,000 | 0 | 0 | 145,464,000 | 0 | 0 | 287,513,000 | 0 | 0 | 222,676,000 | 0 | ||||||
| cash, cash equivalents and restricted cash—end of period | -173,345,000 | 275,613,000 | -43,460,000 | 14,895,000 | 179,150,000 | -2,083,000 | 1,721,000 | 190,908,000 | 45,642,000 | -16,357,000 | 84,680,000 | -19,538,000 | -98,427,000 | 267,719,000 | -10,469,000 | -9,358,000 | 211,493,000 | -9,631,000 | ||||||
| supplemental disclosure of non-cash investing and financing activities: | ||||||||||||||||||||||||
| property and equipment included in accrued expense and accounts payable | 24,000 | 27,000 | 50,000 | 6,000 | 545,000 | -285,000 | -348,000 | 453,000 | 301,000 | 1,229,000 | 97,000 | -70,000 | 36,000 | 5,000 | 35,000 | |||||||||
| deferred offering costs not yet paid | 402,000 | 145,000 | -60,000 | |||||||||||||||||||||
| loss on disposal of property and equipment | 0 | 0 | 0 | 0 | 29,000 | 0 | 0 | 0 | 3,000 | |||||||||||||||
| accounts payable, accrued liabilities, and operating leases | ||||||||||||||||||||||||
| proceeds from controlled equity offering sales agreement, net of commissions | ||||||||||||||||||||||||
| cash, cash equivalents and restricted cash—beginning of year | ||||||||||||||||||||||||
| cash, cash equivalents and restricted cash—end of year | ||||||||||||||||||||||||
| right-of-use assets recognized in exchange for operating leases | 0 | 0 | ||||||||||||||||||||||
| proceeds from controlled equity offering sales agreements | 1,299,000 | 0 | 44,743,000 | 0 | ||||||||||||||||||||
| proceeds from controlled equity offering sales agreement | 7,338,000 | 42,245,000 | ||||||||||||||||||||||
| other | ||||||||||||||||||||||||
| accounts payable and accrued liabilities | 2,017,000 | -4,427,000 | 351,000 | 199,000 | -1,346,000 | 1,060,000 | -3,443,000 | 3,604,000 | 2,448,000 | 2,344,000 | -5,499,000 | 4,370,000 | 610,000 | 234,000 | -11,000 | -1,761,000 | 1,557,000 | |||||||
| net decrease in cash, cash equivalents and restricted cash | 160,000 | 45,642,000 | -16,357,000 | -60,784,000 | -19,538,000 | -11,183,000 | ||||||||||||||||||
| proceeds from issuance of common stock upon public offerings | ||||||||||||||||||||||||
| payment of offering costs | ||||||||||||||||||||||||
| deferred financing costs | 181,000 | |||||||||||||||||||||||
| right-of-use assets recognized in exchange for operating leases under topic 842 | ||||||||||||||||||||||||
| payments of follow-on offering costs | 1,000 | |||||||||||||||||||||||
| right of use asset recognized in exchange for operating lease | ||||||||||||||||||||||||
| right-of-use assets recognized in exchange for operating leases upon adoption of topic 842 | 0 | 0 | 0 | 2,153,000 | ||||||||||||||||||||
| right-of-use asset recognized upon entering into amended lease | ||||||||||||||||||||||||
| payments on capital lease | -1,000 | |||||||||||||||||||||||
| deferred rent | 6,000 | 8,000 | ||||||||||||||||||||||
| proceeds from sale of property and equipment | -1,000 | 0 | ||||||||||||||||||||||
| proceeds from the issuance of common stock upon initial public offering | 0 | |||||||||||||||||||||||
| payments of initial public offering costs | 0 | -1,020,000 | ||||||||||||||||||||||
| proceeds from issuance of convertible preferred stock | ||||||||||||||||||||||||
| preferred stock issuance cost | ||||||||||||||||||||||||
| proceeds from issuance of common stock upon initial public offering | ||||||||||||||||||||||||
| proceeds from exercise of stock options | ||||||||||||||||||||||||
| property and equipment included in accrued expenses and accounts payable | ||||||||||||||||||||||||
| issuance of convertible preferred stock in exchange for simple agreement for future equity | ||||||||||||||||||||||||
| gain/loss on disposal of property and equipment | 0 |
We provide you with 20 years of cash flow statements for Stoke Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Stoke Therapeutics stock. Explore the full financial landscape of Stoke Therapeutics stock with our expertly curated income statements.
The information provided in this report about Stoke Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.